

In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

1. Identification	of the substance or preparation and the company/ undertaking	
1.1 <u>Product Identifier</u>		
Product Name: Mast CAMP Se	lectatab [™] (Preston Blood Free).	
Product Code: MS18		
1.2 <u>Relevant identified uses of the substance or mixture and uses advised against</u>		
Recommended uses: In vitro diagnost	ic product; Laboratory chemical	
Uses advised against: No information a	available	
1.3 Details of supplier of the product and safety data sheet		
Manufacturer/supplier: Mast Group Ltd., Mast House, Derby Road, Boote, Merseyside, UK, L20 IEA Telephone: +44 (0) 151 933 7277 Email: uksales@mastgrp.com Web: www.mastgrp.com Feldstraße 20 23858 Reinfeld Germany Telephone: +49 4533 20 07 34 Email: mast@mast-diagnostica.de Web: www.mastgrp.com UK contact: Telephone: +49 4533 20 07 34 Email: mast@mast-diagnostica.de Web: www.mast_group.com		
	2. Hazards identification	
2.1 <u>Classification of the substance or mixture</u>		
CLP Classification – Regulation (EC) No. 1272/20		
Physical haza		
Heath haza		
Environmental hazards: Based on available data, there are no environmental hazards 2.2 Label elements		
Pictogr	am:	
Signal we	ord: Danger	
Hazard stateme	 H317 May cause an allergic skin reaction. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled 	
Precautionary stateme	 P280 Wear protective gloves. P342 + P311 If experiencing respiratory symptoms: Call a poison centre or doctor/ physician. 	
2.3 <u>Other hazards</u>		
	No information available	



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

3. Composition/information on ingredients

Composition: A multi-component freeze-dried tablet containing cefoperazone in an inert carrier.

Hazardous ingredients:

Component	CAS-No.	EC-No.	Concentration	CLP Classification – 1272/2008/EC	Classification to – 67/548/EEC
Cefoperazone	62893-20-3	263-751-5	23.1%	Skin sensitization Cat. 1: Respiratory sensitization Cat. 1. H317 May cause an allergic skin reaction. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.	Xn - Harmful R42/43 - May cause sensitization by inhalation and skin contact.

4.1 Description of First Aid measures

General advice: Consult a physician. Show this safety data sheet to the doctor in attendance.

Eye contact: Rinse thoroughly with plenty of water for 10 to 15 minutes, also under the eyelids. Obtain medical attention if irritation persists.

First-aid measures

- Skin Contact: Wash off skin thoroughly with soap and plenty of water. Obtain medical attention if irritation persists.
 - Ingestion: Rinse mouth out with plenty of water. Obtain medical attention if symptoms occur.

4.

Inhalation: Move person to fresh air. Obtain medical attention immediately if symptoms occur.

4.2 Most important symptoms and effects, both acute and delayed

No information available.

4.3 Indicate any immediate medical attention and special treatment needed

No information available.

5. Fire fighting measures 5.1 Extinguishing medium Suitable extinguishing media: Use water spray, CO2, foam or dry powder as the extinguisher medium. Extinguishing media which must not be used for safety reasons: No information available 5.2 Special hazards arising from the substance or mixture Combustible material. Thermal decomposition may lead to release of irritating gases and vapours.

5.3 Advice for firefighters

Wear suitable self contained breathing apparatus for fire fighting if necessary.

5.4 Additional information

No data available.



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

	6. Accidental release measures		
6.1	6.1 <u>Personal precautions, protective equipment and emergency procedures</u>		
		Ensure adequate ventilation. W	Jear appropriate protective equipment. Avoid dust formation.
6.2	2 <u>Environmental precautions</u>		
		Should not be released into the	environment.
6.3	3 <u>Methods and materials for containment and cleaning up</u>		
		Sweep up or vacuum up spillag	ge in suitable container for disposal. Avoid dust formation.
6.4	Further information		
		No data available.	
	7. Handling and storage		
7.1	Precautions for safe handlin	g	
	P	Avoid contact with eyes, skin and	d clothing. Avoid ingestion and inhalation. Avoid dust formation.
7.2	Conditions for safe storage,	including any incompatabiliti	<u>es</u>
	S	store at 2°C to 8°C. Keep tightly	y closed in the container provided. Protect from direct sunlight and moisture.
7.3	Specific end use(s)		
	Г	This product is for laboratory use	e only and should only be used by suitably trained laboratory personnel.
		8. Expe	osure controls and personal protection
8.1	Control parameters		
	Components with workspace	e control parameters: This pro	duct has no occupational exposure limits.
8.2	Exposure controls		
	Engineering controls:	No engineering protection req	uired.
	Personal protective measures:	Body protection:	Wear standard microbiology laboratory coat.
		Eye/face protection:	Safety glasses with side shields conforming to EN 166.
		Skin and hand protection:	Handle with suitable gloves conforming to EN 374. Product may be handled with forceps.
		Respiratory protection:	If required use a nuisance type particle respirator type P1 EU EN 143.
	General hygiene measures:	Handle in accordance with goo Wash hands before breaks and	od laboratory practice. I at the end of the working day.



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

9. Physical and Chemical properties

9.1 Information on basic physical and chemical properties

Physical state:	Lyophilised tablet.
Colour:	White to off-white colour.
Odour:	Odourless.
Melting point/freezing point:	No data available.
Initial boiling point/range:	No data available.
Flammability:	No data available.
Lower and upper explosion limit:	No data available.
Flash point:	No data available.
Auto-ignition temperature:	No data available.
Decomposition temperature:	No data available.
pH	No data available.
Kinetic viscosity:	No data available.
Solubility in water/other solvents:	No data available.
Partition coefficient (n-octanol/water):	No data available.
Vapour pressure:	No data available.
Density/Relative density:	No data available.
Relative vapour density:	No data available.
Decomposition temperature	No data available.
Particle characteristics:	No data available.

9.2 Other information

No data available.

10. Stability and reactivity		
10.1 <u>Reactivity</u>		
	No known on information available.	
10.2 <u>Chemical stability</u>		
	Stable under normal conditions.	
10.3 Possibility of hazardous reactions		
	No data available.	
10.4 <u>Conditions to avoid</u>		
	Hygroscopic. Avoid exposure to sunlight.	
10.5 <u>Incompatible materials</u>		
	None known.	
10.6 Hazardous decomposition products		
	None under normal use conditions.	
11 Toxicological information		

11. Toxicological information

11.1 Information on toxicological effects

Overall product information: This product does not present an acute toxicity based on known or supplied information.



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

Acute toxicity:	For cefoperazone - LD50 Oral - rat - >20,000 mg/kg. RTECS: not available Because of the similarity in structure of the penicillins and cephalosporins, those who are allergic to one class of agents may manifest cross-allergenicity when a member of the other class is encountered. Nausea, Vomiting, Diarrhoea, Dermatitis, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Skin corrosion/irritation:	No data available.
Serious eye damage/ eye irritation:	No data available.
Respiratory or skin sensitisation:	May cause allergic respiratory and skin reactions.
Germ cell mutagenicity:	No data available.
Carcinogenicity:	IARC: No component of this product is present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity:	Reproductive toxicity - rat - Intravenous Maternal Effects: Other effects.
Specific target organ toxicity – single exposure:	No data available.
Specific target organ toxicity - repeated exposure:	No data available.
Aspiration hazard:	No data available.
Potential health effects:	Inhalation - May be harmful if inhaled. May cause respiratory tract irritation. Ingestion - May be harmful if swallowed. Skin - May be harmful if absorbed through skin. May cause skin irritation. Eyes - May cause eye irritation.

11.2 <u>Toxicological data for the components</u>

Assess endocrine disrupting properties for human health. This product does not contain any known or suspected endocrine disruptors.

12. Ecological information

12.1 Toxicity

This product is not hazardous to the environment or that are not degradable in waste water treatment plants.

12.2 Persistence and degradability

Expected to be biodegradable.

12.3 Bioaccumulative potential

No data available.

12.4 Mobility in soil

No data available.

12.5 Results of PBT and vPvB assessment

None known.

12.6 Endocrine disrupting properties: requiring you to give product information on adverse effects on the environment caused by endocrine-disrupting properties

This product does not contain any known or suspected endocrine disruptors.

12.7 Other adverse effects

No data available



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

13. Disposal considerations	
Disposal considerations:	 Dispose of in accordance with local and national regulations. Dispose of contaminated waste, e.g. used plates, according to local microbiological rules.
	14. Transport information
14.1 <u>UN Number</u>	
ADR/RID: IMDG: IATA:	Not dangerous for shipping
14.2 <u>UN proper shipping name</u>	
ADR/RID: IMDG: IATA:	Not dangerous for shipping
14.3 <u>Transport hazard class(es)</u>	
ADR/RID: IMDG: IATA:	Not dangerous for shipping
14.4 Packaging group	
ADR/RID: IMDG: IATA:	Not dangerous for shipping
14.5 Environmental hazards	
ADR/RID: IMDG: IATA:	None known.
14.6 Special precautions for user	
	No data available
15. Regulatory information	

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

No data available.

15.2 Chemical safety assessment

Chemical safety assessment reports are not required for mixtures/IVD products.

16. Other information

Original origination date:	17/02/2003
Reason for change to document:	Updated in accordance with Regulation (EC) No 2020/878
	The above information is believed to be correct but does not purport to be all inclusive and shall be used as a guide only. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product and is designed only as a guide for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. Mast Group Ltd. shall not be held liable for any damage resulting from handling or from contact with the above product. See our website at www.mast.grp.com and/or the reverse side of our invoice for additional terms and conditions of sale.